Low sexual desire can be difficult to discuss, especially when it impacts emotional health, relationships, or self-esteem. Bremelanotide is one prescription therapy that has offered an additional option for treating certain types of hypoactive sexual desire disorder (HSDD) in women who are experiencing ongoing problems with sexual desire. This category of treatment relates to a peptide that is commonly known as PT-141 or Nexxana Bremelanotide.
Bremelanotide is not like medications that mainly work on blood flow or hormone levels. Instead, it works on melanocortin receptors in signalling in the brain. This difference makes it an interesting option for eligible premenopausal women, but there are important limitations to its effectiveness, safety profile and approved uses.
Nexxana Bremelanotide is a bremelanotide-based prescription product associated with Nexxana Desire. Nexxana Desire is a medication intended to treat women’s low sexual desire. Bremelanotide is a synthetic peptide acting on melanocortin receptors. It is also known as PT-141 and is the active ingredient in the FDA-approved prescription drug Vyleesi.
There is an important distinction between the active ingredient and the commercial treatment. In 2019, the FDA approved Vyleesi for acquired generalised hypoactive sexual desire disorder in premenopausal women distressed by low sexual desire. Such approval does not mean that each product or formulation sold under another brand is automatically separately approved by the FDA. Consumers should check the actual medication, formulation, prescribing arrangements and dispensing pharmacy.
Nexxana Bremelanotide is therefore best viewed as a prescription bremelanotide treatment rather than an independently established drug category. This is not a general libido booster, not an over-the-counter product, and not a proven treatment for every cause of diminished sexual interest.
Bremelanotide works by activating melanocortin receptors within the CNS. They are involved in diverse biological functions including appetite regulation , pigmentation and sexual response . In women with certain types of HSDD, PT-141 may improve sexual desire by affecting signalling pathways in the brain.
This mechanism is different from treatments that mainly increase blood flow to genital tissues. Bremelanotide does not act like a typical hormone replacement therapy or a direct vasodilator, but rather targets the neural pathways that are responsible for sexual drive and libido. This mechanism has been studied by researchers, as sexual interest is composed of many interrelated elements such as brain activity, emotional responses and physical health.
The exact mechanism of its clinical effects is not completely understood. Therefore, Nexxana Bremelanotide should not be expected to work the same for everyone. It also doesn’t automatically fix relationship problems, psychological distress or medication-related changes in libido, or underlying medical conditions.
The main potential benefit of bremelanotide is improvement in sexual desire in appropriately selected premenopausal women with acquired, generalised HSDD. In clinical trials, desire scores were statistically significantly improved and distress associated with low sexual desire was statistically significantly reduced compared to placebo. This is the clinical evidence for the drug, though improvement doesn't necessarily mean a full return to the previous level of sexual interest.
It may also be useful on an as-needed basis. Conversely, the FDA-approved bremelanotide injection is used as needed rather than as a daily medication. This method may be useful for patients who desire treatment at the time of expected sexual activity. But you do have to plan ahead, since you have to have the injection at least 45 minutes before, and the duration of effectiveness hasn’t been fully determined.
Nexxana Bremelanotide may also appeal to patients looking for a treatment that works through neurological pathways, rather than traditional hormone replacement. This distinction can be important in discussions with your health-care provider about treatment options. However, bremelanotide should not replace evaluation of hormonal, psychological, relational or medical causes of decreased sexual desire.
Research on more than 1,200 women in two pivotal phase 3 trials showed significant improvement in sexual desire and related distress. But the results of trials should be seen in perspective. Not everyone responds, side effects can get in the way of treatment, and the medication is not indicated for sexual enhancement or treating low desire in all populations.
Nausea is the most common side effect of bremelanotide. Other reactions may occur such as flushing, headache, vomiting, irritation at the injection site. In clinical trials, about 40% of patients taking the approved medication reported nausea, and some discontinued treatment due to the severity of the side effect. Nausea can be a major limitation, and while usually less of a problem with subsequent doses, may persist.
Another safety consideration is its effect on cardiovascular measurements. Bremelanotide administration may lead to transient increases in blood pressure and decreases in heart rate. Not to be used by persons with uncontrolled hypertension or a history of heart disease. And for those at high risk of cardiovascular events, careful medical assessment is needed before treatment is even considered.
Focal hyperpigmentation (localised darkening of the skin) has also been described. Changes can include the face, gums and breasts and may not go away completely when treatment stops. The risk is greater the more often it is given and may be greater in people with darker skin. Other precautions may involve interactions with some oral medications, especially those drugs whose absorption may be delayed by delayed gastric emptying. Pregnancy and special considerations regarding opioid-based drugs may also be factors. Full medication and medical history should be reviewed before use.